Analysts Set Perrigo Company plc (NYSE:PRGO) PT at $19.33

Perrigo Company plc (NYSE:PRGO) has been given an average recommendation of “Hold” by the six brokerages that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, four have given a hold rating and one has given a buy rating to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $19.3333.

A number of research firms recently issued reports on PRGO. Weiss Ratings raised Perrigo from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, June 15th. Zacks Research raised shares of Perrigo from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th.

Perrigo Stock Performance

Shares of NYSE:PRGO traded down $0.21 on Friday, hitting $10.20. The company’s stock had a trading volume of 3,394,096 shares, compared to its average volume of 3,964,873. The company has a market capitalization of $1.41 billion, a price-to-earnings ratio of -0.78, a price-to-earnings-growth ratio of 1.21 and a beta of 0.51. The company has a debt-to-equity ratio of 1.45, a quick ratio of 1.59 and a current ratio of 2.72. The stock’s 50-day moving average is $10.80 and its two-hundred day moving average is $12.03. Perrigo has a 12 month low of $9.23 and a 12 month high of $28.43.

Perrigo (NYSE:PRGO) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.43 EPS for the quarter, topping analysts’ consensus estimates of $0.39 by $0.04. Perrigo had a negative net margin of 43.50% and a positive return on equity of 9.96%. The company had revenue of $841.80 million for the quarter, compared to the consensus estimate of $1.04 billion. During the same period in the previous year, the firm earned $0.60 EPS. Perrigo’s revenue was down 7.2% on a year-over-year basis. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. On average, equities research analysts forecast that Perrigo will post 2.11 EPS for the current year.

Perrigo Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 16th. Stockholders of record on Friday, May 29th were issued a $0.29 dividend. The ex-dividend date was Friday, May 29th. This represents a $1.16 dividend on an annualized basis and a dividend yield of 11.4%. Perrigo’s dividend payout ratio is currently -8.85%.

Institutional Investors Weigh In On Perrigo

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. EverSource Wealth Advisors LLC grew its holdings in shares of Perrigo by 116.0% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,888 shares of the company’s stock valued at $26,000 after acquiring an additional 1,014 shares in the last quarter. Geneos Wealth Management Inc. boosted its position in Perrigo by 439.1% during the first quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock valued at $27,000 after purchasing an additional 786 shares during the last quarter. UMB Bank n.a. boosted its position in Perrigo by 161.5% during the fourth quarter. UMB Bank n.a. now owns 1,964 shares of the company’s stock valued at $27,000 after purchasing an additional 1,213 shares during the last quarter. Meeder Asset Management Inc. purchased a new position in Perrigo in the fourth quarter valued at about $28,000. Finally, CWM LLC increased its position in Perrigo by 230.0% in the 4th quarter. CWM LLC now owns 2,191 shares of the company’s stock worth $31,000 after purchasing an additional 1,527 shares during the last quarter. Hedge funds and other institutional investors own 95.91% of the company’s stock.

About Perrigo

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.